Exploring the Impact of Anti-PD-1 and Anti-PD-L1 Agents in Merkel Cell Carcinoma
3 Vues
• 07/17/23
0
0
Intégrer
administrator
Les abonnés
Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses the impact of anti-PD-1 and anti-PD-L1 agents in the treatment of merkel cell carcinoma.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires